-
Something wrong with this record ?
Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia
N. Gökbuget, H. Dombret, S. Giebel, M. Brüggemann, M. Doubek, R. Foa, D. Hoelzer, C. Kim, G. Martinelli, E. Parovichnikova, J. Maria Ribera, M. Schoonen, C. Tuglus, G. Zugmaier, R. Bassan,
Language English Country Great Britain
Document type Journal Article
Grant support
Amgen (Europe) GmBH
Links
PubMed
31876009
DOI
10.1111/ejh.13375
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Antineoplastic Agents therapeutic use MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy pathology MeSH
- Antibodies, Bispecific therapeutic use MeSH
- Recurrence MeSH
- Neoplasm, Residual MeSH
- Aged MeSH
- Standard of Care * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVES: Survival outcomes from a single-arm phase 2 blinatumomab study in patients with minimal residual disease (MRD)-positive B-cell precursor (BCP)-acute lymphoblastic leukaemia (ALL) were compared with those receiving standard of care (SOC) in a historic data set. METHODS: The primary analysis comprised adult Philadelphia chromosome (Ph)-negative patients in first complete haematologic remission (MRD ≥ 10-3 ). Relapse-free survival (RFS) and overall survival (OS) were compared between blinatumomab- and SOC-treatment groups. Baseline differences between groups were adjusted by propensity scores. RESULTS: The primary analysis included 73 and 182 patients from the blinatumomab and historic data sets, respectively. When weighted by age to the blinatumomab-treatment group, median RFS was 7.8 months and median OS was 25.9 months in the SOC-treated group. In the blinatumomab study, median RFS was 35.2 months; median OS was not evaluable. Propensity score weighting achieved balance with seven baseline prognostic factors. With adjustment for haematopoietic stem cell transplantation (HSCT) status, a 50% reduction in risk of relapse or death was observed with blinatumomab vs SOC. Median RFS, unadjusted for HSCT status, was 35.2 months with blinatumomab and 8.3 months with SOC. CONCLUSIONS: These analyses suggest that blinatumomab improves RFS, and possibly OS, in adults with MRD-positive Ph-negative BCP-ALL vs SOC.
'Sapienza' University of Rome Rome Italy
Biostatistics Amgen Inc Thousand Oaks CA USA
Center for Observational Research Amgen Inc Thousand Oaks CA USA
Centre for Observational Research Amgen Ltd Uxbridge UK
Clinical Development Amgen GmbH Munich Germany
Hôpital Saint Louis University Paris Diderot Paris France
ICO Hospital Germans Trias i Pujol Jose Carreras Research Institute Barcelona Spain
J W Goethe University Hospital Frankfurt Germany
Maria Sklodowska Curie Institute Oncology Center Gliwice Poland
National Research Center for Hematology Moscow Russia
Policlinico S Orsola Istituto Seragnoli Bologna Italy
University Hospital and CEITEC Masaryk University Brno Czech Republic
University Hospital Goethe University Frankfurt Germany
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028307
- 003
- CZ-PrNML
- 005
- 20240516084045.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/ejh.13375 $2 doi
- 035 __
- $a (PubMed)31876009
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Gökbuget, Nicola $u University Hospital, Goethe University, Frankfurt, Germany.
- 245 10
- $a Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia / $c N. Gökbuget, H. Dombret, S. Giebel, M. Brüggemann, M. Doubek, R. Foa, D. Hoelzer, C. Kim, G. Martinelli, E. Parovichnikova, J. Maria Ribera, M. Schoonen, C. Tuglus, G. Zugmaier, R. Bassan,
- 520 9_
- $a OBJECTIVES: Survival outcomes from a single-arm phase 2 blinatumomab study in patients with minimal residual disease (MRD)-positive B-cell precursor (BCP)-acute lymphoblastic leukaemia (ALL) were compared with those receiving standard of care (SOC) in a historic data set. METHODS: The primary analysis comprised adult Philadelphia chromosome (Ph)-negative patients in first complete haematologic remission (MRD ≥ 10-3 ). Relapse-free survival (RFS) and overall survival (OS) were compared between blinatumomab- and SOC-treatment groups. Baseline differences between groups were adjusted by propensity scores. RESULTS: The primary analysis included 73 and 182 patients from the blinatumomab and historic data sets, respectively. When weighted by age to the blinatumomab-treatment group, median RFS was 7.8 months and median OS was 25.9 months in the SOC-treated group. In the blinatumomab study, median RFS was 35.2 months; median OS was not evaluable. Propensity score weighting achieved balance with seven baseline prognostic factors. With adjustment for haematopoietic stem cell transplantation (HSCT) status, a 50% reduction in risk of relapse or death was observed with blinatumomab vs SOC. Median RFS, unadjusted for HSCT status, was 35.2 months with blinatumomab and 8.3 months with SOC. CONCLUSIONS: These analyses suggest that blinatumomab improves RFS, and possibly OS, in adults with MRD-positive Ph-negative BCP-ALL vs SOC.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protilátky bispecifické $x terapeutické užití $7 D018033
- 650 _2
- $a antitumorózní látky $x terapeutické užití $7 D000970
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a reziduální nádor $7 D018365
- 650 _2
- $a pre-B-buněčná leukemie $x farmakoterapie $x patologie $7 D015452
- 650 _2
- $a recidiva $7 D012008
- 650 12
- $a standardní péče $7 D059039
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dombret, Hervé $u Hôpital Saint-Louis, University Paris Diderot, Paris, France. $7 xx0316388
- 700 1_
- $a Giebel, Sebastian $u Maria Sklodowska-Curie Institute-Oncology Center, Gliwice, Poland.
- 700 1_
- $a Brüggemann, Monika $u University Hospital Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a Doubek, Michael $u University Hospital and CEITEC Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Foa, Robin $u 'Sapienza' University of Rome, Rome, Italy. $7 xx0317383
- 700 1_
- $a Hoelzer, Dieter $u J.W. Goethe University Hospital, Frankfurt, Germany.
- 700 1_
- $a Kim, Christopher $u Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA.
- 700 1_
- $a Martinelli, Giovanni $u Policlinico S Orsola Istituto Seragnoli, Bologna, Italy.
- 700 1_
- $a Parovichnikova, Elena $u National Research Center for Hematology, Moscow, Russia.
- 700 1_
- $a Maria Ribera, Josep $u ICO-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Barcelona, Spain.
- 700 1_
- $a Schoonen, Marieke $u Centre for Observational Research, Amgen Ltd, Uxbridge, UK.
- 700 1_
- $a Tuglus, Catherine $u Biostatistics, Amgen Inc, Thousand Oaks, CA, USA.
- 700 1_
- $a Zugmaier, Gerhard $u Clinical Development, Amgen (Europe) GmbH, Munich, Germany.
- 700 1_
- $a Bassan, Renato $u UOC Ematologia, Ospedale dell'Angelo, Mestre-Venezia, Italy. $7 xx0317382
- 773 0_
- $w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 104, č. 4 (2020), s. 299-309
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31876009 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20240516084039 $b ABA008
- 999 __
- $a ok $b bmc $g 1608642 $s 1119487
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 104 $c 4 $d 299-309 $e 20200124 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
- GRA __
- $p Amgen (Europe) GmBH
- LZP __
- $a Pubmed-20210105